1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Coleman RE, Lipton A, Roodman GD, et al:
Metastasis and bone loss: advancing treatment and prevention.
Cancer Treat Rev. 36:615–620. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Coleman RE, Marshall H, Cameron D, et al:
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med.
365:1396–1405. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Guise TA, Brufsky A and Coleman RE:
Understanding and optimizing bone health in breast cancer. Curr Med
Res Opin. 26(Suppl 3): S3–S20. 2010. View Article : Google Scholar
|
6
|
Simonet WS, Lacey DL, Dunstan CR, et al:
Osteoprotegerin: a novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar
|
7
|
Tsuda E, Goto M, Mochizuki S, et al:
Isolation of a novel cytokine from human fibroblasts that
specifically inhibits osteoclastogenesis. Biochem Biophys Res
Commun. 234:137–142. 1997. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bucay N, Sarosi I, Dunstan CR, et al:
Osteoprotegerin-deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev. 12:1260–1268. 1998. View Article : Google Scholar : PubMed/NCBI
|
9
|
Buijs JT and van der Pluijm G: Osteotropic
cancers: from primary tumor to bone. Cancer Lett. 273:177–193.
2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Croucher PI, Shipman CM, Lippitt J, et al:
Osteoprotegerin inhibits the development of osteolytic bone disease
in multiple myeloma. Blood. 98:3534–3540. 2001. View Article : Google Scholar : PubMed/NCBI
|
11
|
Corey E, Brown LG, Kiefer JA, et al:
Osteoprotegerin in prostate cancer bone metastasis. Cancer Res.
65:1710–1718. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Fisher JL, Thomas-Mudge RJ, Elliott J, et
al: Osteoprotegerin overexpression by breast cancer cells enhances
orthotopic and osseous tumor growth and contrasts with that
delivered therapeutically. Cancer Res. 66:3620–3628. 2006.
View Article : Google Scholar
|
13
|
Brown JM, Vessella RL, Kostenuik PJ,
Dunstan CR, Lange PH and Corey E: Serum osteoprotegerin levels are
increased in patients with advanced prostate cancer. Clin Cancer
Res. 7:2977–2983. 2001.PubMed/NCBI
|
14
|
Chen G, Sircar K, Aprikian A, Potti A,
Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary
and metastatic human prostate cancer as markers of disease stage
and functional regulation. Cancer. 107:289–298. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zinonos I, Labrinidis A, Lee M, et al:
Anticancer efficacy of Apo2L/TRAIL is retained in the presence of
high and biologically active concentrations of osteoprotegerin in
vivo. J Bone Miner Res. 26:630–643. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Labrinidis A, Diamond P, Martin S, et al:
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine
model of multiple myeloma. Clin Cancer Res. 15:1998–2009. 2009.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Endo-Munoz L, Cumming A, Rickwood D, et
al: Loss of osteoclasts contributes to development of osteosarcoma
pulmonary metastases. Cancer Res. 70:7063–7072. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Luo KW, Ko CH, Yue GG, et al: Anti-tumor
and anti-osteolysis effects of the metronomic use of zoledronic
acid in primary and metastatic breast cancer mouse models. Cancer
Lett. 339:42–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Body JJ, Diel IJ, Bell R, et al: Oral
ibandronate improves bone pain and preserves quality of life in
patients with skeletal metastases due to breast cancer. Pain.
111:306–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Brufsky AM, Bosserman LD, Caradonna RR, et
al: Zoledronic acid effectively prevents aromatase
inhibitor-associated bone loss in postmenopausal women with early
breast cancer receiving adjuvant letrozole: Z-FAST study 36-month
follow-up results. Clin Breast Cancer. 9:77–85. 2009. View Article : Google Scholar
|
21
|
Bundred NJ, Campbell ID, Davidson N, et
al: Effective inhibition of aromatase inhibitor-associated bone
loss by zoledronic acid in postmenopausal women with early breast
cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer.
112:1001–1010. 2008. View Article : Google Scholar
|
22
|
Paterson AH, Powles TJ, Kanis JA,
McCloskey E, Hanson J and Ashley S: Double-blind controlled trial
of oral clodronate in patients with bone metastases from breast
cancer. J Clin Oncol. 11:59–65. 1993.PubMed/NCBI
|
23
|
Rosen LS, Gordon D, Kaminski M, et al:
Zoledronic acid versus pamidronate in the treatment of skeletal
metastases in patients with breast cancer or osteolytic lesions of
multiple myeloma: a phase III, double-blind, comparative trial.
Cancer J. 7:377–387. 2001.
|
24
|
Rosen LS, Gordon D, Tchekmedyian S, et al:
Zoledronic acid versus placebo in the treatment of skeletal
metastases in patients with lung cancer and other solid tumors: a
phase III, double-blind, randomized trial - the Zoledronic Acid
Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol.
21:3150–3157. 2003. View Article : Google Scholar
|